Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative

Adriana C. Gamboa, Mohammad Y. Zaidi, Rachel M. Lee, Shelby Speegle, Jeffrey M. Switchenko, Joseph Lipscomb, Jordan M. Cloyd, Ahmed Ahmed, Travis Grotz, Jennifer Leiting, Keith Fournier, Andrew J. Lee, Sean Dineen, Benjamin D. Powers, Andrew M. Lowy, Nikhil V. Kotha, Callisia Clarke, T. Clark Gamblin, Sameer H. Patel, Tiffany C. LeeLaura Lambert, Ryan J. Hendrix, Daniel E. Abbott, Kara Vande Walle, Kelly Lafaro, Byrne Lee, Fabian M. Johnston, Jonathan Greer, Maria C. Russell, Charles A. Staley, Shishir K. Maithel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: No guidelines exist for surveillance following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal and colorectal cancer. The primary objective was to define the optimal surveillance frequency after CRS/HIPEC. Methods: The U.S. HIPEC Collaborative database (2000–2017) was reviewed for patients who underwent a CCR0/1 CRS/HIPEC for appendiceal or colorectal cancer. Radiologic surveillance frequency was divided into two categories: low-frequency surveillance (LFS) at q6–12mos or high-frequency surveillance (HFS) at q2–4mos. Primary outcome was overall survival (OS). Results: Among 975 patients, the median age was 55 year, 41% were male: 31% had non-invasive appendiceal (n = 301), 45% invasive appendiceal (n = 435), and 24% colorectal cancer (CRC; n = 239). With a median follow-up time of 25 mos, the median time to recurrence was 12 mos. Despite less surveillance, LFS patients had no decrease in median OS (non-invasive appendiceal: 106 vs. 65 mos, p < 0.01; invasive appendiceal: 120 vs. 73 mos, p = 0.02; colorectal cancer [CRC]: 35 vs. 30 mos, p = 0.8). LFS patients had lower median PCI scores compared with HFS (non-invasive appendiceal: 10 vs. 19; invasive appendiceal: 10 vs. 14; CRC: 8 vs. 11; all p < 0.01). However, on multivariable analysis, accounting for PCI score, LFS was still not associated with decreased OS for any histologic type (non-invasive appendiceal: hazard ratio [HR]: 0.28, p = 0.1; invasive appendiceal: HR: 0.73, p = 0.42; CRC: HR: 1.14, p = 0.59). When estimating annual incident cases of CRS/HIPEC at 375 for non-invasive appendiceal, 375 invasive appendiceal and 4410 colorectal, LFS compared with HFS for the initial two post-operative years would potentially save $13–19 M/year to the U.S. healthcare system. Conclusions: Low-frequency surveillance after CRS/HIPEC for appendiceal or colorectal cancer is not associated with decreased survival, and when considering decreased costs, may optimize resource utilization.

Original languageEnglish (US)
Pages (from-to)134-146
Number of pages13
JournalAnnals of surgical oncology
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

Appendiceal Neoplasms
Colorectal Neoplasms
Drug Therapy
Survival
Databases
Guidelines
Delivery of Health Care

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms : A Multi-institutional Analysis of the US HIPEC Collaborative. / Gamboa, Adriana C.; Zaidi, Mohammad Y.; Lee, Rachel M.; Speegle, Shelby; Switchenko, Jeffrey M.; Lipscomb, Joseph; Cloyd, Jordan M.; Ahmed, Ahmed; Grotz, Travis; Leiting, Jennifer; Fournier, Keith; Lee, Andrew J.; Dineen, Sean; Powers, Benjamin D.; Lowy, Andrew M.; Kotha, Nikhil V.; Clarke, Callisia; Gamblin, T. Clark; Patel, Sameer H.; Lee, Tiffany C.; Lambert, Laura; Hendrix, Ryan J.; Abbott, Daniel E.; Vande Walle, Kara; Lafaro, Kelly; Lee, Byrne; Johnston, Fabian M.; Greer, Jonathan; Russell, Maria C.; Staley, Charles A.; Maithel, Shishir K.

In: Annals of surgical oncology, Vol. 27, No. 1, 01.01.2020, p. 134-146.

Research output: Contribution to journalArticle

Gamboa, AC, Zaidi, MY, Lee, RM, Speegle, S, Switchenko, JM, Lipscomb, J, Cloyd, JM, Ahmed, A, Grotz, T, Leiting, J, Fournier, K, Lee, AJ, Dineen, S, Powers, BD, Lowy, AM, Kotha, NV, Clarke, C, Gamblin, TC, Patel, SH, Lee, TC, Lambert, L, Hendrix, RJ, Abbott, DE, Vande Walle, K, Lafaro, K, Lee, B, Johnston, FM, Greer, J, Russell, MC, Staley, CA & Maithel, SK 2020, 'Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative', Annals of surgical oncology, vol. 27, no. 1, pp. 134-146. https://doi.org/10.1245/s10434-019-07526-1
Gamboa, Adriana C. ; Zaidi, Mohammad Y. ; Lee, Rachel M. ; Speegle, Shelby ; Switchenko, Jeffrey M. ; Lipscomb, Joseph ; Cloyd, Jordan M. ; Ahmed, Ahmed ; Grotz, Travis ; Leiting, Jennifer ; Fournier, Keith ; Lee, Andrew J. ; Dineen, Sean ; Powers, Benjamin D. ; Lowy, Andrew M. ; Kotha, Nikhil V. ; Clarke, Callisia ; Gamblin, T. Clark ; Patel, Sameer H. ; Lee, Tiffany C. ; Lambert, Laura ; Hendrix, Ryan J. ; Abbott, Daniel E. ; Vande Walle, Kara ; Lafaro, Kelly ; Lee, Byrne ; Johnston, Fabian M. ; Greer, Jonathan ; Russell, Maria C. ; Staley, Charles A. ; Maithel, Shishir K. / Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms : A Multi-institutional Analysis of the US HIPEC Collaborative. In: Annals of surgical oncology. 2020 ; Vol. 27, No. 1. pp. 134-146.
@article{45de13dd9bd0440ebf4ebbcfb79f0f9a,
title = "Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative",
abstract = "Background: No guidelines exist for surveillance following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal and colorectal cancer. The primary objective was to define the optimal surveillance frequency after CRS/HIPEC. Methods: The U.S. HIPEC Collaborative database (2000–2017) was reviewed for patients who underwent a CCR0/1 CRS/HIPEC for appendiceal or colorectal cancer. Radiologic surveillance frequency was divided into two categories: low-frequency surveillance (LFS) at q6–12mos or high-frequency surveillance (HFS) at q2–4mos. Primary outcome was overall survival (OS). Results: Among 975 patients, the median age was 55 year, 41{\%} were male: 31{\%} had non-invasive appendiceal (n = 301), 45{\%} invasive appendiceal (n = 435), and 24{\%} colorectal cancer (CRC; n = 239). With a median follow-up time of 25 mos, the median time to recurrence was 12 mos. Despite less surveillance, LFS patients had no decrease in median OS (non-invasive appendiceal: 106 vs. 65 mos, p < 0.01; invasive appendiceal: 120 vs. 73 mos, p = 0.02; colorectal cancer [CRC]: 35 vs. 30 mos, p = 0.8). LFS patients had lower median PCI scores compared with HFS (non-invasive appendiceal: 10 vs. 19; invasive appendiceal: 10 vs. 14; CRC: 8 vs. 11; all p < 0.01). However, on multivariable analysis, accounting for PCI score, LFS was still not associated with decreased OS for any histologic type (non-invasive appendiceal: hazard ratio [HR]: 0.28, p = 0.1; invasive appendiceal: HR: 0.73, p = 0.42; CRC: HR: 1.14, p = 0.59). When estimating annual incident cases of CRS/HIPEC at 375 for non-invasive appendiceal, 375 invasive appendiceal and 4410 colorectal, LFS compared with HFS for the initial two post-operative years would potentially save $13–19 M/year to the U.S. healthcare system. Conclusions: Low-frequency surveillance after CRS/HIPEC for appendiceal or colorectal cancer is not associated with decreased survival, and when considering decreased costs, may optimize resource utilization.",
author = "Gamboa, {Adriana C.} and Zaidi, {Mohammad Y.} and Lee, {Rachel M.} and Shelby Speegle and Switchenko, {Jeffrey M.} and Joseph Lipscomb and Cloyd, {Jordan M.} and Ahmed Ahmed and Travis Grotz and Jennifer Leiting and Keith Fournier and Lee, {Andrew J.} and Sean Dineen and Powers, {Benjamin D.} and Lowy, {Andrew M.} and Kotha, {Nikhil V.} and Callisia Clarke and Gamblin, {T. Clark} and Patel, {Sameer H.} and Lee, {Tiffany C.} and Laura Lambert and Hendrix, {Ryan J.} and Abbott, {Daniel E.} and {Vande Walle}, Kara and Kelly Lafaro and Byrne Lee and Johnston, {Fabian M.} and Jonathan Greer and Russell, {Maria C.} and Staley, {Charles A.} and Maithel, {Shishir K.}",
year = "2020",
month = "1",
day = "1",
doi = "10.1245/s10434-019-07526-1",
language = "English (US)",
volume = "27",
pages = "134--146",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms

T2 - A Multi-institutional Analysis of the US HIPEC Collaborative

AU - Gamboa, Adriana C.

AU - Zaidi, Mohammad Y.

AU - Lee, Rachel M.

AU - Speegle, Shelby

AU - Switchenko, Jeffrey M.

AU - Lipscomb, Joseph

AU - Cloyd, Jordan M.

AU - Ahmed, Ahmed

AU - Grotz, Travis

AU - Leiting, Jennifer

AU - Fournier, Keith

AU - Lee, Andrew J.

AU - Dineen, Sean

AU - Powers, Benjamin D.

AU - Lowy, Andrew M.

AU - Kotha, Nikhil V.

AU - Clarke, Callisia

AU - Gamblin, T. Clark

AU - Patel, Sameer H.

AU - Lee, Tiffany C.

AU - Lambert, Laura

AU - Hendrix, Ryan J.

AU - Abbott, Daniel E.

AU - Vande Walle, Kara

AU - Lafaro, Kelly

AU - Lee, Byrne

AU - Johnston, Fabian M.

AU - Greer, Jonathan

AU - Russell, Maria C.

AU - Staley, Charles A.

AU - Maithel, Shishir K.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Background: No guidelines exist for surveillance following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal and colorectal cancer. The primary objective was to define the optimal surveillance frequency after CRS/HIPEC. Methods: The U.S. HIPEC Collaborative database (2000–2017) was reviewed for patients who underwent a CCR0/1 CRS/HIPEC for appendiceal or colorectal cancer. Radiologic surveillance frequency was divided into two categories: low-frequency surveillance (LFS) at q6–12mos or high-frequency surveillance (HFS) at q2–4mos. Primary outcome was overall survival (OS). Results: Among 975 patients, the median age was 55 year, 41% were male: 31% had non-invasive appendiceal (n = 301), 45% invasive appendiceal (n = 435), and 24% colorectal cancer (CRC; n = 239). With a median follow-up time of 25 mos, the median time to recurrence was 12 mos. Despite less surveillance, LFS patients had no decrease in median OS (non-invasive appendiceal: 106 vs. 65 mos, p < 0.01; invasive appendiceal: 120 vs. 73 mos, p = 0.02; colorectal cancer [CRC]: 35 vs. 30 mos, p = 0.8). LFS patients had lower median PCI scores compared with HFS (non-invasive appendiceal: 10 vs. 19; invasive appendiceal: 10 vs. 14; CRC: 8 vs. 11; all p < 0.01). However, on multivariable analysis, accounting for PCI score, LFS was still not associated with decreased OS for any histologic type (non-invasive appendiceal: hazard ratio [HR]: 0.28, p = 0.1; invasive appendiceal: HR: 0.73, p = 0.42; CRC: HR: 1.14, p = 0.59). When estimating annual incident cases of CRS/HIPEC at 375 for non-invasive appendiceal, 375 invasive appendiceal and 4410 colorectal, LFS compared with HFS for the initial two post-operative years would potentially save $13–19 M/year to the U.S. healthcare system. Conclusions: Low-frequency surveillance after CRS/HIPEC for appendiceal or colorectal cancer is not associated with decreased survival, and when considering decreased costs, may optimize resource utilization.

AB - Background: No guidelines exist for surveillance following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal and colorectal cancer. The primary objective was to define the optimal surveillance frequency after CRS/HIPEC. Methods: The U.S. HIPEC Collaborative database (2000–2017) was reviewed for patients who underwent a CCR0/1 CRS/HIPEC for appendiceal or colorectal cancer. Radiologic surveillance frequency was divided into two categories: low-frequency surveillance (LFS) at q6–12mos or high-frequency surveillance (HFS) at q2–4mos. Primary outcome was overall survival (OS). Results: Among 975 patients, the median age was 55 year, 41% were male: 31% had non-invasive appendiceal (n = 301), 45% invasive appendiceal (n = 435), and 24% colorectal cancer (CRC; n = 239). With a median follow-up time of 25 mos, the median time to recurrence was 12 mos. Despite less surveillance, LFS patients had no decrease in median OS (non-invasive appendiceal: 106 vs. 65 mos, p < 0.01; invasive appendiceal: 120 vs. 73 mos, p = 0.02; colorectal cancer [CRC]: 35 vs. 30 mos, p = 0.8). LFS patients had lower median PCI scores compared with HFS (non-invasive appendiceal: 10 vs. 19; invasive appendiceal: 10 vs. 14; CRC: 8 vs. 11; all p < 0.01). However, on multivariable analysis, accounting for PCI score, LFS was still not associated with decreased OS for any histologic type (non-invasive appendiceal: hazard ratio [HR]: 0.28, p = 0.1; invasive appendiceal: HR: 0.73, p = 0.42; CRC: HR: 1.14, p = 0.59). When estimating annual incident cases of CRS/HIPEC at 375 for non-invasive appendiceal, 375 invasive appendiceal and 4410 colorectal, LFS compared with HFS for the initial two post-operative years would potentially save $13–19 M/year to the U.S. healthcare system. Conclusions: Low-frequency surveillance after CRS/HIPEC for appendiceal or colorectal cancer is not associated with decreased survival, and when considering decreased costs, may optimize resource utilization.

UR - http://www.scopus.com/inward/record.url?scp=85068213309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068213309&partnerID=8YFLogxK

U2 - 10.1245/s10434-019-07526-1

DO - 10.1245/s10434-019-07526-1

M3 - Article

AN - SCOPUS:85068213309

VL - 27

SP - 134

EP - 146

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 1

ER -